Advances in Chronic Kidney Disease
Volume 11, Issue 4 , Pages 361-370, October 2004

Outcomes associated with hypogonadism in women with chronic kidney disease

  • José R. Weisinger

      Affiliations

    • Division of Nephrology, Hospital Universitario de Caracas, Universidad Central de Venezuela, Caracas, Venezuela
    • Corresponding Author InformationAddress correspondence to José R. Weisinger, MD, FACP, Division of Nephrology, Hospital Universitario de Caracas, Universidad Central de Venezuela, Apartado Postal 47365, Los Chaguaramos, Caracas, Venezuela
  • ,
  • Ezequiel Bellorin-Font

      Affiliations

    • Division of Nephrology, Hospital Universitario de Caracas, Universidad Central de Venezuela, Caracas, Venezuela

The successful use of renal replacement therapy has resulted in longer survival and a population of older patients with chronic kidney disease (CKD) that includes patients with other significant preexisting illnesses. In this review, we analyze the short-term and long-term outcomes associated to persisting hypogonadism in CKD patients. The short-term manifestations, commonly observed in normal postmenopausal women, are either a rare complaint of women with CKD or are frequently attributed to the uremic state. These symptoms include hot flashes, sleep disturbances and depression, sexual dysfunction, vaginal dryness and atrophy, urinary incontinence, and skin aging and wrinkling. The long-term outcomes of hypogonadism have potentially devastating effects on bone, cardiovascular system, and cognitive function, which could significantly alter the quality of life and survival of women with stage 5 CKD (CKD-5). Postmenopausal osteoporosis has been recognized as an important entity associated with renal osteodystrophy, and efforts have begun to tackle the reduced bone-mineral density (BMD) and increased fracture rate seen in this population. Similarly, cardiovascular disease represents the major cause of death in the CKD-5 population, with a 10 to 20 times greater mortality than in the general population. The accumulating evidence for a possible link between osteoporosis and atherosclerosis is discussed, as well as new directions in the understanding of postmenopausal osteoporosis in the context of renal bone disease, under the guidance of the Global Bone and Mineral Initiative endorsed by the Kidney Disease: Improving Global Outcomes initiative. Nephrologists must face gynecological issues with their women patients and design interdisciplinary clinical studies that include strategies that utilize well-tested and newer drug regimens in the management of osteoporosis, cardiovascular disease, and other postmenopausal manifestations in CKD-5 patients.

Index words:  Osteoporosis , chronic kidney disease , hemodialysis , atherosclerosis , cardiovascular disease , menopause

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This study was supported by grant G-97-008808 of the Fondo Nacional de Ciencia, Tecnología y Innovación de Venezuela (FONACIT) and Fundarenal-HUC.

PII: S1548-5595(04)00122-3

doi:10.1053/j.ackd.2004.07.009

Advances in Chronic Kidney Disease
Volume 11, Issue 4 , Pages 361-370, October 2004